Methods and compositions using miR-3151 in the diagnosis and treatment of thyroid cancer
Compositions comprising therapeutic oligonucleotide miR-3151 compounds that target the expression of genes associated with tumorigenesis or cell transformation are provided.
1. A method of treating a subject having a papillary thyroid cancer having a decreased expression of miR-3151, the method comprising:
administering an effective amount of a miR-3151 gene product sufficient to increase expression of miR-3151, wherein the levels of miR-3151 are increased after administration, thereby treating the subject.
2. The method of claim 1 , further comprising:
measuring the expression of at least one biomarker in a biological sample from the subject, wherein the at least one biomarker is selected from the group consisting of: gene products of BAALC and miR-3151;
comparing the expression of the at least one biomarker to a corresponding control;
determining whether the expression of either BAALC or miR-3151 is low as compared to the control;
administering the miR-3151 gene product if the expression of either BAALC or miR-3151 is low, in an amount sufficient to modulate expression of one or more of BAALC and miR-3151;
wherein the levels of one or more of BAALC and miR-3151 are increased after administration, thereby treating the subject.
3. The method of claim 1 , wherein the subject is a human.